Trial Profile
A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women With Breast Cancer and Established Bone Metastases (MBD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary) ; Zoledronic acid
- Indications Advanced breast cancer; Cancer metastases
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 05 Sep 2008 Results presented at ASCO breast cancer symposium 2008.
- 30 Jun 2008 Results presented at the VII International Meeting on Cancer Induced Bone Disease.
- 11 Jun 2008 Results were presented at the 44th American Society of Clinical Oncology (ASCO) annual meeting.